145 related articles for article (PubMed ID: 37123024)
1. Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest
Naoi Y; Tsunashima R; Shimazu K; Oikawa M; Imanishi S; Koyama H; Kamada Y; Ishihara K; Suzuki M; Osako T; Kinoshita T; Suto A; Nakamura S; Tsuda H; Noguchi S
Oncol Lett; 2023 May; 25(5):209. PubMed ID: 37123024
[TBL] [Abstract][Full Text] [Related]
2. Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer.
Tsukamoto F; Arihiro K; Takahashi M; Ito KI; Ohsumi S; Takashima S; Oba T; Yoshida M; Kishi K; Yamagishi K; Kinoshita T
BMC Cancer; 2021 Oct; 21(1):1077. PubMed ID: 34610807
[TBL] [Abstract][Full Text] [Related]
3. Development of recurrence risk score using 95‑gene classifier and its application to formalin‑fixed paraffin‑embedded tissues in ER‑positive, HER2‑negative and node‑negative breast cancer.
Naoi Y; Saito Y; Kishi K; Shimoda M; Kagara N; Miyake T; Tanei T; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2019 Dec; 42(6):2680-2685. PubMed ID: 31638234
[TBL] [Abstract][Full Text] [Related]
4. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
5. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores.
Fujii T; Masuda H; Cheng YC; Yang F; Sahin AA; Naoi Y; Matsunaga Y; Raghavendra A; Sinha AK; Fernandez JRE; James A; Yamagishi K; Matsushima T; Schuetz R; Tripathy D; Tada S; Jackson RS; Noguchi S; Nakamura S; Acoba JD; Ueno NT
Breast Cancer Res Treat; 2021 Sep; 189(2):455-461. PubMed ID: 34131830
[TBL] [Abstract][Full Text] [Related]
6. Multi-gene classifiers for prediction of recurrence in breast cancer patients.
Naoi Y; Noguchi S
Breast Cancer; 2016 Jan; 23(1):12-18. PubMed ID: 25700572
[TBL] [Abstract][Full Text] [Related]
7. Multi-gene assay 95- and 155-gene classifiers for prognosis prediction and chemotherapy omission in lymphnode positive luminal-type breast cancer.
Matsumoto S; Tsunashima R; Kitano S; Watanabe A; Kato C; Morita M; Sakaguchi K; Győrffy B; Naoi Y
Cancer Treat Res Commun; 2023; 36():100711. PubMed ID: 37245351
[TBL] [Abstract][Full Text] [Related]
8. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M; Imoto S; Ishida T; Ito Y; Iwata H; Masuda N; Mukai H; Saji S; Shimizu A; Ikeda T; Haga H; Saeki T; Aogi K; Sugie T; Ueno T; Kinoshita T; Kai Y; Kitada M; Sato Y; Jimbo K; Sato N; Ishiguro H; Takada M; Ohashi Y; Ohno S
Lancet Oncol; 2021 Jan; 22(1):74-84. PubMed ID: 33387497
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
[TBL] [Abstract][Full Text] [Related]
11. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Johnston SRD; Toi M; O'Shaughnessy J; Rastogi P; Campone M; Neven P; Huang CS; Huober J; Jaliffe GG; Cicin I; Tolaney SM; Goetz MP; Rugo HS; Senkus E; Testa L; Del Mastro L; Shimizu C; Wei R; Shahir A; Munoz M; San Antonio B; André V; Harbeck N; Martin M;
Lancet Oncol; 2023 Jan; 24(1):77-90. PubMed ID: 36493792
[TBL] [Abstract][Full Text] [Related]
12. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation.
Prat A; Guarneri V; Paré L; Griguolo G; Pascual T; Dieci MV; Chic N; González-Farré B; Frassoldati A; Sanfeliu E; Cejalvo JM; Muñoz M; Bisagni G; Brasó-Maristany F; Urso L; Vidal M; Brandes AA; Adamo B; Musolino A; Miglietta F; Conte B; Oliveira M; Saura C; Pernas S; Alarcón J; Llombart-Cussac A; Cortés J; Manso L; López R; Ciruelos E; Schettini F; Villagrasa P; Carey LA; Perou CM; Piacentini F; D'Amico R; Tagliafico E; Parker JS; Conte P
Lancet Oncol; 2020 Nov; 21(11):1455-1464. PubMed ID: 33152285
[TBL] [Abstract][Full Text] [Related]
13. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer.
Kubo M
Chin Clin Oncol; 2020 Jun; 9(3):33. PubMed ID: 32527118
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer.
Poorvu PD; Gelber SI; Rosenberg SM; Ruddy KJ; Tamimi RM; Collins LC; Peppercorn J; Schapira L; Borges VF; Come SE; Warner E; Jakubowski DM; Russell C; Winer EP; Partridge AH
J Clin Oncol; 2020 Mar; 38(7):725-733. PubMed ID: 31809240
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
17. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
18. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
[TBL] [Abstract][Full Text] [Related]
19. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
